KRAS and ovarian carcinoma: Although lacking evidence from LUAD, several studies have suggested that aberrant KRAS signaling is responsible for triggering immunological responses and inflammation-driven tumorigenesis, in which a marked induction of CSF2 expression has been observed in an ovarian cancer cell line36 and colorectal cancer patients with progression37.